57例原发鼻腔NK-T细胞淋巴瘤临床分析  

Clinical Analysis of 57 Patients with Nasal Cavity NK/T-cell lymphoma

作　　者：何斌[1] 沈学明[1] 段诗苗[1] 彭开桂[1] 张亚军[1] 刘静景[1] 

机构地区：[1]安徽省蚌埠医学院第一附属医院放疗科,233004

出　　处：《中华全科医学》2009年第11期1162-1163,共2页Chinese Journal of General Practice

摘　　要：目的探讨原发鼻腔NK-T细胞淋巴瘤临床特征、治疗及影响预后因素。方法收集蚌埠医学院附属医院1995年1月-2003年7月收治的原发鼻腔NK-T细胞淋巴瘤57例,按照Ann Arbor分期标准,ⅠE期30例,ⅡE期21例,Ⅲ期4例,Ⅳ期2例。单纯放疗27例,放化疗30例。结果全组中位生存62个月,5年总生存率单纯放疗组、放化疗联合治疗组分别为64.0%、56.0%;中位生存期分别为64个月、61个月,差异无统计学意义(P>0.05)。分析显示,硬腭和/或鼻中隔穿孔、PS评分、发热等B症状与预后关系密切,AnnArbor分期仍然是影响生存率的主要因素(P<0.05)。结论原发鼻腔NK/T细胞淋巴瘤早期治疗是关键,放疗联合化疗未改善预后。Objective To investigate the clinical feature, treatment outcome and prognosis of nasal NK/T-cell lymphoma. Methods From January 1995 to July 2004,57 patients with nasal cavity NK/T-cell lymphoma were treated in our hospital. According to the Ann Arbor staging classification,there were 30 stage Ⅰ E,21 stage Ⅱ E,4 stage Ⅲ and 2 stage ⅣE. Patients received radiation therapy （27 cases） , combination of radiation and chemotherapy（ 30 cases ）. Results The median overall survival time was 62 months. The 5-year overall survival（OS） of patients who received chemoradiotherapy was 64.0% ,and those who received radiotherapy alone was 56.0%. The median survival time was 64 months ,61 months respectively, which was no difference （ P 〉 0.05 ）. Analysis showed that perforation of hard palate and/or nasal septum, B symptoms and therapeutic modality were most important prognostic factors of nasal NK/T-cell lymphoma, and Ann Arbor stage was still main factor of survival（ P 〈 0.05 ）. Conclusion Treatment in early stage was crucial for nasal cavity NK/T-cell lymphon：a; radiotherapy combined with chemotherapy can not improve the survival.

关 键 词：鼻肿瘤 淋巴瘤 NK/T细胞 预后 

分 类 号：R739.62[医药卫生—肿瘤] R733.41[医药卫生—临床医学]